Pulmonx (LUNG) Other Non-Current Liabilities (2019 - 2022)
Pulmonx's (LUNG) quarterly Other Non-Current Liabilities came in at $179000.0 in Q2 2022, little changed quarter-over-quarter from $179000.0 in Q1 2022.
Powered by 
Analysis
Pulmonx (LUNG) Other Non-Current Liabilities (2019 - 2022) Analysis & Trends
Pulmonx (LUNG) has reported Other Non-Current Liabilities for 4 consecutive years, with $179000.0 the latest figure, recorded in Q2 2022.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $179000.0 in Q2 2022; TTM through Jun 2022 was $179000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $179000.0, changed N/A from the prior year.
- Other Non-Current Liabilities was $179000.0 for Q2 2022 at Pulmonx, roughly flat from $179000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.9 million in Q3 2020 and troughed at $179000.0 in Q4 2021.
- A 4-year average of $727400.0 and a median of $179000.0 in 2021 frame the typical range for Other Non-Current Liabilities.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn |
| 10 | Pulmonx | 75.94 Mn | 6.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 179,000.00 |
| Mar 31, 2022 | 179,000.00 |
| Dec 31, 2021 | 179,000.00 |
| Sep 30, 2020 | 1.90 Mn |
| Dec 31, 2019 | 1.20 Mn |